Description
Humulin (insulin human and insulin human) is an insulin listed in our Insulin directory and prescribed for blood glucose control in diabetes (1.1) (2.1). Administered via the subcutaneous route, Humulin is available for delivery to U.S. residents through Canadian Pharmacy Store with a valid prescription. Review the clinical fact table, dosage directions, cautions, drug interactions, side effects, and official regulatory sources below.
Humulin is a medication containing the active pharmaceutical ingredient insulin human and insulin human, classified pharmacologically as an insulin (2.1). It is clinically indicated for the management of blood glucose control in diabetes as part of a comprehensive treatment plan supervised by a licensed healthcare provider (2.1).
Within the Insulin section of our catalogue, patients and prescribers frequently review Humulin alongside related therapies such as Novolin Penfills & Vials (NPH), Admelog (Insulin Lispro), Apidra (Insulin Glulisine), and Basaglar (Insulin Glargine).
Official Indications and Usage
Humulin is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. (1.1)
Mechanism of Action and Pharmacology
Humulin N lowers blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulins inhibit lipolysis and proteolysis, and enhance protein synthesis. (1.1) (1.1)
What is Type 1 diabetes?
Type 1 diabetes develops when the body makes little or no insulin. Insulin treatment replaces a hormone needed to manage blood glucose. Explore related medications below and discuss treatment options with your healthcare provider. Read our complete Type 1 diabetes condition guide for appointment questions and related therapies (3.1).
What is Type 2 diabetes?
Type 2 diabetes involves high blood glucose because the body does not use insulin effectively and may not make enough. Treatment depends on individual glucose, heart, kidney, and other health needs. Explore related medications below and discuss treatment options with your healthcare provider. Read our complete Type 2 diabetes condition guide for appointment questions and related therapies (3.1).
Ordering Humulin from Canada for U.S. Delivery
U.S. patients can order Humulin (Insulin Isophane) in U.S. dollars with a valid prescription from a U.S.-licensed clinician. Your card is only charged after your prescription passes pharmacist safety checks and is ready to ship.
Step 1
Send Your Prescription
- Valid Rx required from a U.S.-licensed physician, NP, or PA (Rx rules).
- Upload Rx online, request a pharmacy transfer, or have your doctor fax (844) 666 – 6819.
- Order up to a 90-day personal-use supply per shipment (refill planning).
Step 2
Pharmacist Safety Check
- Multi-point dosing and interaction review completed in under 1 business day.
- Mandatory licensed pharmacist consultation via phone, voicemail, or text before dispatch.
- Verified under our Pharmacy Safety Standards.
Step 3
$29.99 USD Cold-Chain Cooler
- Packed in an insulated thermal cooler with gel packs and temperature indicators for $29.99 USD.
- Tracked via Canada Post and USPS: 3 to 7 business days from Canada (7 to 14 days from international partners).
- Review full shipping and delivery details.
Step 4
U.S. Street Delivery & Payment
- Delivered to any physical U.S. street address with signature upon delivery (no P.O. Boxes).
- You see and approve the country of origin upfront before your card is charged.
- Report any delayed or damaged parcel within 48 hours for prompt resolution.
Fact Table
| Clinical Specification | Details |
|---|---|
| Brand / Product Name | Humulin |
| Chemical / Generic Name | Insulin Human And Insulin Human |
| Pharmacological Class | Insulin |
| Therapeutic Category | Insulin |
| Molecular Formula | C257H383N65O77S6 (2.1) |
| Molecular Weight | 5808 g/mol (2.1) |
| Elimination Half-Life | ~4.4 hours (1.1) |
| Legal Status | Check the selected product requirements |
| Regulatory Reference Authorities | U.S. FDA (DailyMed), Health Canada (DPD), NIH PubChem, NLM MedlinePlus |
| Routes of Administration | Subcutaneous |
| Dosage Forms & Strengths | Injectable suspension: 100 units/mL (U-100) white and cloudy suspension available as: 10 mL multiple-dose vial 3 mL single-patient-use Humulin N KwikPen |
| Primary Indications | Blood Glucose Control In Diabetes |
| Pregnancy & Breastfeeding | Consult Doctor / Prescriber before use |
| PubChem CID | 118984375 |
| FDA UNII Identifier | 1Y17CTI5SR |
| NLM RxNorm Concept ID (RxCUI) | 311026, 311028, 847199, 1654862 |
| FDA Application License | BLA018781 |
| Official DailyMed SetID | f6edd793-440b-40c2-96b5-c16133b7a921 |
| Catalogue Index Links | Letter H Index · All Medications · All Categories |
Directions
Dosage and Administration Overview
Only administer subcutaneously (in abdominal wall, thigh, upper arm, or buttocks). Rotate injection sites to reduce risk of lipodystrophy and localized cutaneous amyloidosis. Individualize and adjust dosage based on metabolic needs, blood glucose monitoring results and glycemic control goal. May use with a meal-time insulin if indicated. (1.1)
Presentations and Strengths
Injectable suspension: 100 units/mL (U-100) white and cloudy suspension available as: 10 mL multiple-dose vial 3 mL single-patient-use Humulin N KwikPen prefilled pen Injectable suspension: 100 units/mL (U-100) available as: 10 mL multiple-dose vial 3 mL single-patient-use Humulin ® N KwikPen ® prefilled pen. (1.1)
Administration Guidance
Humulin is administered by injection according to your prescriber’s individualized dosing schedule (1.1). Always verify the concentration, pen or vial presentation, and dose markings prior to administration, rotate injection sites as instructed, and never share injection pens, needles, or cartridges between patients.
Missed Dose Guidance
If you miss a scheduled dose of Humulin, follow the missed-dose instructions in the official patient leaflet or ask your pharmacist. Do not double the next dose to make up for a missed dose (2.1).
Ingredients
Active Pharmaceutical Ingredient
The active ingredient in Humulin is insulin human and insulin human (molecular formula C257H383N65O77S6, molecular weight 5808 g/mol) (2.1) (2.1).
Excipients and Formulation Carriers
Film coatings, stabilizers, and inactive carriers vary by strength and manufacturer presentation. If you have a known allergy to lactose, dyes, sulfites, or specific preservatives, ask our pharmacist to check the exact excipient list for your selected package (2.1).
Cautions and important safety information
Contraindications
Humulin is contraindicated: During episodes of hypoglycemia, and In patients who have had hypersensitivity reactions to Humulin N or any of its excipients. (1.1)
Key Clinical Precautions
Before starting or continuing Humulin, discuss your complete medical history with your healthcare provider. Key clinical cautions include (1.1):
- Heart failure: Fluid retention or cardiovascular workload changes may precipitate or worsen congestive heart failure in susceptible patients. Report sudden weight gain, shortness of breath, or ankle and leg swelling to your healthcare provider.
- Hypoglycemia (low blood sugar): When used alongside insulin therapies or insulin secretagogues (such as sulfonylureas), the risk of hypoglycemia increases. Patients may need a lower dose of their secretagogue or insulin and should recognize symptoms like shakiness, sweating, fast heartbeat, dizziness, and confusion.
- Hypersensitivity and anaphylaxis: Serious allergic reactions, including anaphylaxis, angioedema, and severe rash, have been reported. Discontinue use and seek immediate medical care if swelling of the face, lips, tongue, or throat or difficulty breathing occurs.
- Seizure threshold: This medication may lower the seizure threshold or require caution in patients with a history of seizure disorders or conditions that predispose to seizures.
Pregnancy, Lactation, and Special Populations
Available data from published studies over decades have not established an association with human insulin use during pregnancy and major birth defects, miscarriage, or adverse maternal or fetal outcomes. There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy. Animal reproduction studies were not performed. The estimated background risk of major birth defects is 6-10% in women with pre-gestational diabetes with a HbA1c >7% and has been reported to be as high as 20-25% in women with a HbA1c >10%. The estimated background risk of miscarriage for the indicated population is unknown. (1.1)
Interactions
Official Drug Interaction Overview
N Drugs that May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics Intervention: Dose adjustment and increased frequency of glucose monitoring may be required when Humulin N is co-administered with these drugs. Drugs that May Decrease the Blood Glucose Lowering Effect of Humulin N Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (1.1)
Important Interaction Categories
Concomitant use of Humulin with certain prescription medications, over-the-counter drugs, or supplements can alter how the medication works or increase the risk of side effects. Important interaction categories to review with your prescriber and pharmacist include (2.1):
- Lithium: This medication may alter renal lithium clearance, either increasing serum lithium levels (risking lithium toxicity) or decreasing lithium concentrations (reducing therapeutic efficacy). Serum lithium levels should be monitored closely when starting, adjusting, or stopping therapy.
- Monoamine oxidase inhibitors (MAOIs, such as phenelzine, tranylcypromine, selegiline, or linezolid): Concomitant use or use within 14 days of stopping an MAOI can cause severe drug interactions, including hypertensive crisis, serotonin syndrome, or enhanced hypoglycemic and central nervous system effects.
- Alcohol: Excessive alcohol consumption can potentiate blood-sugar fluctuations, increase the risk of lactic acidosis or ketoacidosis in metabolic therapies, heighten gastrointestinal irritation, or increase drowsiness and orthostatic dizziness.
Side effects
Clinical Trial and Postmarketing Adverse Reactions
Adverse reactions have been identified during post-approval use of Humulin N. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or to establish a causal relationship to drug exposure. Adverse reactions observed with Humulin N include hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, weight gain, and edema. Allergic Reactions Some patients taking Humulin N have experienced erythema, local edema, and pruritus at the site of injection. These conditions were usually self-limiting. (1.1)
When to Seek Immediate Medical Attention
Contact your physician or seek urgent medical care if you experience signs of a severe allergic reaction (hives, difficulty breathing, or swelling of the face, lips, tongue, or throat), severe dizziness or fainting, unexplained severe pain, or any sudden change in your clinical symptoms (2.1).
Storage and handling
Handling Dispense in the original sealed carton with the enclosed Instructions for Use. Protect from heat and light. Do not freeze. Do not use if it has been frozen. See Table 2 below for storage conditions. (1.1)
Temperature-Sensitive Storage
Keep unopened packages refrigerated within the temperature range specified on the manufacturer's carton (typically 2°C to 8°C / 36°F to 46°F). Do not freeze. Once in use, follow the exact in-use storage temperature and discard calendar printed on your specific pen, vial, or cartridge leaflet (2.1).
Frequently Asked Questions About Humulin
What is Humulin and what active ingredient does it contain?
Humulin is an insulin containing the active pharmaceutical ingredient insulin human and insulin human (chemical formula C257H383N65O77S6). It is supplied for subcutaneous administration and requires a valid prescription where applicable.
How does Humulin work in the body?
Humulin N lowers blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulins inhibit lipolysis and proteolysis, and enhance protein synthesis.
What conditions is Humulin prescribed to treat?
Humulin is primarily indicated for blood glucose control in diabetes. Your prescribing clinician determines the appropriate indication, strength, and treatment duration based on your individual diagnosis and medical history.
How should I take or use Humulin?
Follow the exact dosage, frequency, and administration instructions printed on your prescription label. Humulin is administered via the subcutaneous route. Administer it consistently at the same time(s) as directed, and never adjust your dose or stop therapy without speaking with your prescriber.
What are the most common side effects of Humulin?
Side effects depend on the dose, route of administration, and individual health factors. Review the official prescribing leaflet with your pharmacist and report any unusual or severe symptoms promptly.
What medications or substances can interact with Humulin?
Important interaction categories for Humulin include lithium, monoamine oxidase inhibitors, and alcohol. Always share a complete list of your prescription drugs, over-the-counter medicines, vitamins, and herbal supplements with your pharmacist before starting treatment.
Can Humulin be used during pregnancy or breastfeeding?
If you are pregnant, planning to become pregnant, or breastfeeding, consult your prescribing physician before using Humulin to weigh the clinical benefits and potential risks.
Do I need a prescription to buy Humulin online from Canada?
Yes. A valid prescription written by a U.S.-licensed physician, nurse practitioner, or physician assistant is required to buy Humulin (Insulin Isophane) through our licensed Canadian pharmacy partners. Valid prescriptions go through multiple safety checks in less than 1 business day, followed by a mandatory request to speak with a licensed pharmacist for a consultation (watch your phone, voicemails, and text messages).
Does Humulin have a generic equivalent (Insulin Isophane) at a Canada pharmacy?
Currently, Humulin (Insulin Isophane) is dispensed in our catalogue as a brand-name formulation. Check our Insulin Isophane active ingredient hub for updates as licensed generic presentations become available.
How is Humulin shipped to U.S. residents, and how much does shipping cost?
Humulin requires Cold-Chain temperature-sensitive handling at a flat rate of $29.99 USD per order. Once your prescription passes safety checks (<1 business day) and you complete the mandatory licensed pharmacist consultation (check your voicemails and text messages), Humulin is packed in a medication-specific insulated thermal cooler with cold gel packs, seasonal packaging adjustments, and temperature indicators, and shipped from Manitoba, Canada via Canada Post and USPS (3 to 7 business days) with full tracking. A physical U.S. street address (no P.O. Boxes) and signature upon delivery are required.
How can I send or transfer my Humulin prescription, or ask about an unlisted strength?
You can upload a clear photo or PDF of your Humulin prescription online, request a prescription transfer or direct prescriber coordination from our team, or have your prescriber fax the prescription directly to (844) 666 – 6819. You may order up to a 90-day personal-use supply per shipment. If you do not see your exact prescribed strength or manufacturer listed, call 1-888-868-1920 and our staff will check availability across our licensed pharmacy partners.
References & Official Sources
Clinical, pharmacological, and safety facts for Humulin (Insulin Isophane) are compiled directly from official regulatory prescribing labels and primary biomedical databases:
- (1.1) Humulin N (insulin human) injection, Suspension [eli lilly and company]. U.S. National Library of Medicine / U.S. Food and Drug Administration (DailyMed). Official U.S. FDA / DailyMed Structured Product Labeling (SPL). (Accessed 2026-10-29).
- (2.1) PubChem Compound Summary for cid 118984375 (Insulin Human). National Center for Biotechnology Information (NCBI), U.S. National Library of Medicine. Official regulatory & clinical reference. (Accessed 2026-10-29).
- (3.1) MedlinePlus Medical Encyclopedia: Diabetes Type 1. MedlinePlus / National Library of Medicine. U.S. National Library of Medicine, MedlinePlus Drug & Health Information. (Accessed 2026-10-29).
- (4.1) MedlinePlus Medical Encyclopedia: Diabetes Type 2. MedlinePlus / National Library of Medicine. U.S. National Library of Medicine, MedlinePlus Drug & Health Information. (Accessed 2026-10-29).
- (5.1) Health Canada Drug Product Database (DPD), Authorized Product Records. Health Canada / Government of Canada. Health Canada Drug Product Database & Official Product Monograph. (Accessed 2026-10-29).

Source: Canada